BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, March 25, 2026
Home » Newsletters » BioWorld MedTech

BioWorld MedTech

Jan. 6, 2022

View Archived Issues
Deal-handshake-wire-frame.png

Stryker acquires Vocera in $3B cash deal

Stryker Corp. reported that it signed a definitive merger agreement to acquire Vocera Communications Inc. for $2.97 billion in an all-cash transaction expected to close in the first quarter of this year. Vocera provides digital care and communication services, which Stryker said will designed to help hospitals connect caregivers and various data-generating medical devices such as wearables, paired beds, ambulation equipment, badges and alarms. Read More
IVF

AI fertility company secures $6M for global expansion

Canadian company Future Fertility Inc. is hatching plans to expand the user base for its flagship egg prediction software product, Violet, for egg cryopreservation. The noninvasive image analysis tool uses artificial intelligence (AI) to evaluate the reproductive potential of mature eggs. Investors are backing the Toronto-based company with $6 million in series A funds, so it can expand internationally and develop additional assessment products. Read More
Bonescalpel device

Bioventus feeling good in its bones following FDA clearance of Bonescalpel

Bioventus Inc. has received FDA 510(k) clearance for a device that enables surgeons to remove bone in hard-to-work spaces during minimally invasive surgery. It acquired the company that developed the tool, Great Neck, N.Y.-based Misonix Inc., in October. Read More

Researchers develop X-ray phase-contrast imaging for use in osteoarthritis

PARIS – A team of researchers from the Université Grenoble Alpes, France, has been working on X-ray phase-contrast imaging (PCI) for investigating osteoarthritis. The team at the Inserm Synchrotron Radiation for Biomedicine (Strobe) laboratory in Grenoble, France has spent the last five years working with Grenoble-based firm Novitom SAS on this new imaging modality for osteoarticular conditions. Read More
Glucose testing

The enzyme NOX4 is essential for the antidiabetes effect of exercise

In a recent study, investigators led by Tony Tiganis at Monash University, Australia have identified that upregulation of the enzyme NOX4 (NADPH oxidase 4) boosted levels of reactive oxygen species and protected development of insulin resistance in both aged as well as obese mice. Read More

Appointments and advancements for Jan. 6, 2022

New hires and promotions in the med-tech industry, including: Bluewind Medical, Forza Innovations, Nexus Spine, Veracyte, The Wound Pros. Read More

Financings for Jan. 6, 2022

Med-tech firms raising money in public or private financings, including: Virtue Diagnostics. Read More

In the clinic for Jan. 6, 2022

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Median Technologies, Transmedics. Read More

Other news to note for Jan. 6, 2022

Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Delta Medical, Illumina, Mainz Biomed, Nanovibronix, Natera, Pillar, Socpra, Somalogic. Read More

Regulatory actions for Jan. 6, 2022

Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Jelikalite, Vy Spine. Read More

Popular Stories

  • Today's news in brief

    BioWorld
  • MRI image brain on black background

    ADPD 2026: Can we prevent dementia? Scientists quantify it

    BioWorld
    Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
  • Illustration of Alzheimer's disease in the brain

    ADPD 2026: Three inflection points to target Alzheimer’s disease

    BioWorld Science
    A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
  • Art concept for Parkinson's disease

    Emerging therapeutic strategies for Parkinson’s at ADPD 2026

    BioWorld
    Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for March 24, 2026
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing